Fintel reports that on March 28, 2025, Leerink Partners downgraded their outlook for Equillium (NasdaqCM:EQ) from Outperform ...

Fintel reports that on March 28, 2025, Leerink Partners downgraded their outlook for Equillium (LSE:0A4D) from Outperform to Market Perform. There are 35 funds or institutions reporting positions ...

Fintel reports that on March 24, 2025, Leerink Partners initiated coverage of Medpace Holdings (NasdaqGS:MEDP) with a Market ...

In a report released on March 24, David Risinger from Leerink Partners maintained a Buy rating on AnaptysBio (ANAB – Research Report). The ...

Opthea (NASDAQ:OPT – Get Free Report) was downgraded by research analysts at Leerink Partners from an “outperform” rating to ...

Shares of EQ stock opened at $0.41 on Friday. Equillium has a 12 month low of $0.37 and a 12 month high of $2.43. The firm has a market cap of $14.36 million, a PE ratio of -2.90 and a beta of 1. ...

Sales of Beta Bionics insulin pumps spiked 145% in the fourth quarter behind solid new patient starts. Elsewhere, former ...

Leerink Partners analyst Thomas Smith reiterated a Buy rating on Immunovant (IMVT – Research Report) yesterday and set a price target of ...

today announced that the Company’s Management will participate in a fireside chat at the Leerink Partners Global Healthcare Conference on Monday, March 10, 2025 at 4:20 PM EST and participate in ...

Brady, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the 2025 Leerink Partners Global Healthcare Conference in Miami, Florida.

Fintel reports that on March 24, 2025, Leerink Partners initiated coverage of Medpace Holdings (BMV:MEDP) with a Market Perform recommendation. Invesco holds 1,085K shares representing 3.56% ...

INDIANAPOLIS, Feb. 28, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in Leerink Partners Global Healthcare Conference on March 10, 2025. Lucas Montarce, Lilly executive ...